Cutting things down to size
by Kevin Hrusovsky and
Mark Roskey
PDF
version (152 KB PDF)
A disparity between pharmaceutical industry levels of R&D investment and the
development of innovative drugs exists in part because technology innovation has
been focused on optimizing individual processes. Broad use of standardized technologies,
such as microfluidics, can help scientists move and share better-quality data
across therapeutic areas or between R&D groups.
PAT pending
by Randall C. Willis
PDF
version (216 KB PDF)
Technical innovation in pharmaceutical manufacturing has been relatively slow
compared with that in drug R&D, with many methods used for process analysis
remaining largely unchanged for decades. To address this problem and ensure the
safety and efficacy of drug production, the FDA has developed process analytical
technology guidelines for quality testing.
Connecting the dots
by Tom Laz, Kevin Fisher, Mitch Kostich, and Mark Atkinson
PDF
version (360 KB PDF)
Technical innovation in pharmaceutical manufacturing has been relatively slow
compared with that in drug R&D, with many methods used for process analysis
remaining largely unchanged for decades. To address this problem and ensure the
safety and efficacy of drug production, the FDA has developed process analytical
technology guidelines for quality testing.
BioValley
by Allison L. Byrum
PDF
version (156 KB PDF)
Nestled at the junction of France, Germany, and Switzerland, BioValley strives
to become a leading biotechnology region in Europe, and its trinational status
affords it some unique opportunities. The young biocluster is building a network
ranging from universities and research institutions to major pharmaceutical firms. |